Zim Laboratories Ltd

Surging to a fresh 52-week high of Rs 142.05 on 10 Sep 2026, Zim Laboratories Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a subdued Sensex environment.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite this moderation in valuation appeal, the stock has demonstrated robust price performance year-to-date, significantly outperforming the broader Sensex index.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a previously fair valuation to an attractive one. Despite a recent day decline of 4.23%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a renewed price attractiveness relative to its historical levels and peer group, offering investors a fresh perspective on its market positioning.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zim Laboratories Ltd has demonstrated a significant shift in price momentum, supported by a series of technical indicator upgrades that suggest a bullish outlook. The stock’s recent surge, with a day change of 12.36%, reflects renewed investor interest amid improving technical signals, positioning it as a noteworthy contender in the Pharmaceuticals & Biotechnology sector.

Surging past its previous peaks, Zim Laboratories Ltd touched a fresh 52-week high of Rs 135.8 on 2 Sep 2026, marking a remarkable 73.03% gain over the past year despite a broadly declining Sensex. This milestone underscores the stock’s strong price momentum and technical resilience amid a volatile market backdrop.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock has demonstrated notable resilience with a year-to-date return of 72%, significantly outperforming the Sensex’s negative 9.7% over the same period.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite impressive year-to-date returns of 72.5%, the company’s elevated price-to-earnings (P/E) ratio and other valuation metrics suggest a more cautious outlook compared to its peers and historical averages.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 August 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Zim Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite its micro-cap status and a Mojo Grade of Sell, the stock’s recent price action and technical indicators suggest a potential turnaround, supported by strong returns year-to-date and over the past year, outperforming the broader Sensex significantly.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 August 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trend, and technical outlook.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s price action and technical parameters suggest a cautiously optimistic outlook amid ongoing volatility.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in technical momentum, moving from a mildly bullish to a bullish stance. Despite mixed returns relative to the Sensex over various periods, recent technical indicators suggest an improving price momentum that could influence investor sentiment positively.

At Rs 120.18, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Zim Laboratories Ltd locked at its upper circuit of 5% on 6 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 1.04%, the stock’s technical indicators present a complex picture, with some metrics signalling strength while others suggest caution. This analysis delves into the latest technical parameters, price momentum, and comparative market performance to provide investors with a comprehensive view of Zim Laboratories’ current positioning.

Zim Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 May 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 01 August 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.